Milan Scheidegger
Leader of Psychedelic Research at University of Zurich
Data updated
Research Footprint
Milan Scheidegger appears in 23 tracked papers (2015–2026) and 1 clinical trial, most studied alongside Ayahuasca, DMT and Psilocybin, across Healthy Volunteers, Depressive Disorders and Neuroimaging & Brain Measures.
Most-cited paper: Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers (320 citations).
Frequent co-authors: Dominik Dornbierer, Daniel Meling and Helena Aicher.
Publication Landscape
How the 23 papers Blossom tracks for Milan Scheidegger line up by year, topic, and journal. These are the psychedelic-relevant papers in Blossom's records as of July 2026, not a complete bibliography.
How has Milan Scheidegger's publishing grown?
SourcedTracked papers by publication year. Click a year for the running total.
Don't read as total output: only the 23 of 23 tracked papers with a recorded publication date are counted, and these are the psychedelic-relevant papers Blossom tracks, not a complete bibliography. The current year is still filling in.
What does Milan Scheidegger publish on?
SourcedTracked papers per topic. Orange marks the largest research focus.
Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Where does Milan Scheidegger publish?
SourcedTracked papers per journal. Orange marks the most-used journal.
Counts the journal recorded on each tracked paper; preprints and papers with no journal on file are not shown. These are the psychedelic-relevant papers Blossom tracks, not a complete bibliography.
Background & Research
Milan Scheidegger leads the Psychedelic Research & Therapy Development group in Zurich. With a background in medicine, neuroscience, and philosophy, he develops novel formulations for DMT and 5-MeO-DMT. His translational research explores how psychedelic-induced plasticity can be harnessed to facilitate healing and transformative experiences in both clinical and naturalistic settings.
Key Impact
Investigates how psychedelics enhance neurobehavioral plasticity and support psychotherapy.
Collaboration Network
28 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Milan Scheidegger's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Milan Scheidegger is associated with.
University of Zurich
academicWithin the 'Department of Psychiatry, Psychotherapy and Psychosomatics' at the University of Zurich, Dr Milan Scheidegger is leading a team conducting psychedelic research and therapy development. Researchers here are investigating the therapeutic potential of psychedelics to reverse maladaptive neurobehavioral patterns in stress-related mood disorders and to enhance psychotherapeutic learning capabilities.
View stakeholder →Reconnect Labs
Private BiotechReconnect Labs AG is a Swiss clinical-stage company and University of Zurich spin-off developing precision psychopharmacology therapeutics, including sublingual DMT/harmine, sublingual 5-MeO-DMT, and sublingual dexmedetomidine. Founded in 2021 by Dr. Davor Kosanic (CEO) and co-founders from the Psychiatric University Clinic Zurich and ETH Zurich, building on ~30 years of in-human psychedelic research. The company raised CHF 22M+ (CHF 12M equity across Seed 2021 and Series A 2023–2025; CHF 10M in competitive grants from investors including Esperante Ventures, Lionheart Ventures, Negev Capital, and Noetic Fund) before emerging from stealth in August 2025. Their microcarrier-based transmucosal delivery platform (exclusively licensed) dramatically reduces inter-subject PK variability for DMT/harmine vs. oral ayahuasca and eliminates vomiting. RE03 (sublingual dexmedetomidine for insomnia in PTSD) is the most advanced programme with Swissmedic approval and FDA accelerated pathway confirmed.
View stakeholder →